News about Richard Tyson

Spun out of Oxford University in the 1960s, Oxford Instruments has developed a reputation for leading technology and scientific expertise among academics, researchers and top companies the world over. Cryostats are just one product in the portfolio. Ultra-powerful microscopes help to develop new drugs and advanced industrial materials. And sophisticated fabrication kit is critical to the development of next-generation semiconductors. Oxford Instruments is a force for good - a British company whose top-notch kit is helping to find new drugs, drive scientific discoveries and make waves across the industrial plain. At £26.25, the shares deserve to move higher. A long-term buy.

The FTSE 250 firm, which makes and sells x-ray cameras, microscopes and magnets to academic researchers and commercial customers, is buying a Zurich-based company for £15m. FemtoTools designs and makes precision nanoindenters that measure the force needed to pierce a hole in a material. Richard Tyson, chief executive of Oxford Instruments, said the company will be an 'excellent addition' to its portfolio.

Following an approach by a consortium of CVC Partners and Francisco Partner Funds, shares in the FTSE 250 payments provider Network International soared 22%. Dechra Pharmaceuticals reported that it was in negotiations with private equity company EQT over a potential £4.6 billion settlement following the market close. The news arrived too late for traders to react, but the stock would be in sharp relief when trading resumes.